{"id":"peginterferon-alfa","safety":{"commonSideEffects":[{"rate":"50-90","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-70","effect":"Headache"},{"rate":"10-50","effect":"Neutropenia"},{"rate":"5-30","effect":"Thrombocytopenia"},{"rate":"5-20","effect":"Depression and psychiatric effects"},{"rate":"5-15","effect":"Thyroid dysfunction"},{"rate":"10-40","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":{"setId":"d9290e5b-6d40-2318-e053-2995a90a9916","title":"PEGASYS (PEGINTERFERON ALFA-2A) INJECTION, SOLUTION [PHARMAAND GMBH]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa binds to interferon-alpha receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. This leads to enhanced natural killer cell and cytotoxic T-lymphocyte activity, making it effective against chronic viral infections and certain malignancies. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to unmodified interferon-alpha.","oneSentence":"Peginterferon alfa is an interferon-alpha protein conjugated with polyethylene glycol that activates innate and adaptive immune responses to suppress viral replication and inhibit cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:09.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Certain hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":"Adult T-cell Leukemia-Lymphoma, ATLL","enrollment":15},{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT00442572","phase":"PHASE2","title":"SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07-03","conditions":"Hepatitis B, Chronic","enrollment":21},{"nctId":"NCT06707922","phase":"NA","title":"A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2022-03-18","conditions":"Chronic Hepatitis B","enrollment":350},{"nctId":"NCT03852433","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-31","conditions":"Chronic Hepatitis Delta","enrollment":175},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT04226950","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-01-10","conditions":"Essential Thrombocytopenia","enrollment":40},{"nctId":"NCT05395507","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-01","conditions":"Essential Thrombocytopenia","enrollment":194},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT04640129","phase":"PHASE4","title":"HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-01-01","conditions":"Liver Fibrosis","enrollment":336},{"nctId":"NCT05941845","phase":"PHASE2","title":"Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-07-24","conditions":"Membranous Nephropathy","enrollment":5},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT01369212","phase":"PHASE3","title":"Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-11","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT01439776","phase":"PHASE4","title":"Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients","status":"COMPLETED","sponsor":"Hanyang University","startDate":"2011-09","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT00062816","phase":"PHASE1, PHASE2","title":"Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2003-06","conditions":"Hepatitis C, Chronic","enrollment":22},{"nctId":"NCT02430181","phase":"PHASE2","title":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-11","conditions":"Chronic Hepatitis D Infection","enrollment":21},{"nctId":"NCT01369199","phase":"PHASE3","title":"Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-05","conditions":"Hepatitis B","enrollment":28},{"nctId":"NCT01368497","phase":"PHASE3","title":"Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-09","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT03575208","phase":"PHASE2","title":"Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2019-02-13","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT03181113","phase":"","title":"Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2016-05-18","conditions":"Hepatitis B","enrollment":473},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT04517539","phase":"PHASE2","title":"Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-12-01","conditions":"Thymic Epithelial Tumor","enrollment":65},{"nctId":"NCT03957629","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-11-06","conditions":"Hepatitis B, Liver Fibrosis","enrollment":186},{"nctId":"NCT02407080","phase":"PHASE1","title":"Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia","status":"COMPLETED","sponsor":"John Mascarenhas","startDate":"2015-04","conditions":"Polycythemia Vera, Essential Thrombocythemia","enrollment":13},{"nctId":"NCT03552549","phase":"PHASE2, PHASE3","title":"SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-08-05","conditions":"Melanoma","enrollment":126},{"nctId":"NCT03920605","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-01","conditions":"Hepatitis B, Liver Fibrosis","enrollment":100},{"nctId":"NCT03919565","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-01","conditions":"Hepatitis B, Liver Fibrosis","enrollment":120},{"nctId":"NCT03801538","phase":"PHASE4","title":"The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-01-01","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02745704","phase":"PHASE4","title":"The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-04","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02838810","phase":"PHASE4","title":"The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-06","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT01088659","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-16","conditions":"Hepatitis D, Chronic","enrollment":50},{"nctId":"NCT03098121","phase":"PHASE4","title":"Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection","status":"COMPLETED","sponsor":"Taoyuan General Hospital","startDate":"2017-10-20","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT03733652","phase":"NA","title":"Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-11-15","conditions":"Chronic Hepatitis b, Efficacy, Self","enrollment":100},{"nctId":"NCT01429792","phase":"PHASE4","title":"A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-25","conditions":"Hepatitis C, Chronic","enrollment":1013},{"nctId":"NCT02103439","phase":"PHASE3","title":"An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-06-06","conditions":"Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection","enrollment":140},{"nctId":"NCT01758588","phase":"PHASE2","title":"Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-01","conditions":"Myelofibrosis","enrollment":8},{"nctId":"NCT01889433","phase":"PHASE3","title":"An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-07-10","conditions":"Hepatitis, Hepatitis C","enrollment":170},{"nctId":"NCT02908763","phase":"PHASE4","title":"HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-08","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02893124","phase":"PHASE4","title":"The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-08","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT01033448","phase":"PHASE4","title":"A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Hepatitis C, Chronic","enrollment":59},{"nctId":"NCT01730508","phase":"","title":"An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11-20","conditions":"Hepatitis B, Chronic","enrollment":978},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00423670","phase":"PHASE2","title":"Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":765},{"nctId":"NCT00104052","phase":"PHASE3","title":"Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT00248339","phase":"PHASE3","title":"Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2002-05","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT00467077","phase":"PHASE2","title":"Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"California Cancer Consortium","startDate":"2004-09","conditions":"Kidney Cancer","enrollment":21},{"nctId":"NCT01980290","phase":"","title":"Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2013-05","conditions":"Hepatitis, Chronic","enrollment":50},{"nctId":"NCT00861406","phase":"PHASE1","title":"Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-10","conditions":"Melanoma","enrollment":38},{"nctId":"NCT01628692","phase":"PHASE2","title":"Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus","enrollment":230},{"nctId":"NCT02829775","phase":"PHASE2, PHASE3","title":"A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma","enrollment":9},{"nctId":"NCT01937728","phase":"PHASE4","title":"Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-03","conditions":"Hepatitis C","enrollment":542},{"nctId":"NCT02063607","phase":"PHASE1","title":"The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2013-12","conditions":"Hepatitis C","enrollment":60},{"nctId":"NCT02118597","phase":"","title":"An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2014-05","conditions":"Hepatitis C, Chronic","enrollment":19},{"nctId":"NCT01285050","phase":"PHASE4","title":"Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2011-01","conditions":"HIV Infection, Hepatitis C","enrollment":20},{"nctId":"NCT01337375","phase":"PHASE1","title":"A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Hepatitis C, Chronic","enrollment":31},{"nctId":"NCT00940420","phase":"PHASE4","title":"A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-10","conditions":"Hepatitis C, Chronic","enrollment":2695},{"nctId":"NCT01798576","phase":"","title":"An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT02894918","phase":"PHASE4","title":"A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2016-09","conditions":"Chronic Hepatitis B","enrollment":114},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT01258101","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Hepatitis C, Chronic","enrollment":395},{"nctId":"NCT02822547","phase":"PHASE4","title":"Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2015-03","conditions":"Chronic Hepatitis B","enrollment":253},{"nctId":"NCT00700401","phase":"","title":"POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":262},{"nctId":"NCT00747539","phase":"","title":"Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-07","conditions":"HIV, Hepatitis C, Infections","enrollment":330},{"nctId":"NCT00522249","phase":"PHASE1, PHASE2","title":"Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2007-05","conditions":"Carcinoma, Renal Cell","enrollment":10},{"nctId":"NCT01471574","phase":"PHASE3","title":"Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C, Genotype 1","enrollment":549},{"nctId":"NCT00241241","phase":"PHASE2","title":"Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera","status":"COMPLETED","sponsor":"PV-Nord","startDate":"2004-09","conditions":"Polycythemia Vera","enrollment":40},{"nctId":"NCT00160251","phase":"PHASE2","title":"Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Chronic Hepatitis C","enrollment":357},{"nctId":"NCT01170962","phase":"PHASE2","title":"Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":512},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01718158","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01","conditions":"Hepatitis C","enrollment":444},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01573351","phase":"PHASE3","title":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":398},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT02112630","phase":"NA","title":"Boceprevir in End Stage Renal Disease (ESRD)","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-05","conditions":"Hepatitis C Infection, End Stage Renal Disease","enrollment":""},{"nctId":"NCT01740089","phase":"PHASE2, PHASE3","title":"Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biocad","startDate":"2011-11","conditions":"Hepatitis, Hepatitis C","enrollment":150},{"nctId":"NCT01508286","phase":"","title":"Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen-Cilag International NV","startDate":"","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00856024","phase":"","title":"ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Chronic","enrollment":902},{"nctId":"NCT00633230","phase":"PHASE1","title":"Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"","conditions":"Hepatitis C Virus","enrollment":""},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01459913","phase":"PHASE3","title":"Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT01467479","phase":"PHASE3","title":"A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-12","conditions":"Hepatitis C","enrollment":185},{"nctId":"NCT00797745","phase":"PHASE2","title":"A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":111},{"nctId":"NCT02339337","phase":"PHASE4","title":"A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-06","conditions":"HBV/HCV Co-infection","enrollment":203},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT01769833","phase":"PHASE3","title":"HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2013-05","conditions":"Chronic Hepatitis B","enrollment":144},{"nctId":"NCT01335529","phase":"PHASE2","title":"Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-05","conditions":"HCV Coinfection, HIV-1 Infection","enrollment":69},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT01197157","phase":"PHASE2, PHASE3","title":"Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2010-09","conditions":"Hepatitis C","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":1925,"reaction":"ANAEMIA"},{"count":1160,"reaction":"RASH"},{"count":1056,"reaction":"FATIGUE"},{"count":1017,"reaction":"NAUSEA"},{"count":607,"reaction":"PRURITUS"},{"count":603,"reaction":"WHITE BLOOD CELL COUNT DECREASED"},{"count":542,"reaction":"DECREASED APPETITE"},{"count":542,"reaction":"HAEMOGLOBIN DECREASED"},{"count":521,"reaction":"PYREXIA"},{"count":501,"reaction":"DEPRESSION"}],"_approvalHistory":[],"publicationCount":905,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEG-IFN","peginterferon alfa-2a or peginterferon alfa-2b"],"phase":"marketed","status":"active","brandName":"Peginterferon Alfa","genericName":"Peginterferon Alfa","companyName":"Third Affiliated Hospital, Sun Yat-Sen University","companyId":"third-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon alfa is an interferon-alpha protein conjugated with polyethylene glycol that activates innate and adaptive immune responses to suppress viral replication and inhibit cell proliferation. Used for Chronic hepatitis B, Chronic hepatitis C, Certain hematologic malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}